Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease.
Identifieur interne : 001A79 ( PubMed/Curation ); précédent : 001A78; suivant : 001A80Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease.
Auteurs : Seung Hun Lee [Corée du Sud] ; Mi Jung Kim ; Beom-Jun Kim ; Sung Reul Kim ; Sail Chun ; Jin Sook Ryu ; Ghi Su Kim ; Myoung Chong Lee ; Jung-Min Koh ; Sun Ju ChungSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2010.
English descriptors
- KwdEn :
- Absorptiometry, Photon (methods), Aged, Analysis of Variance, Anthropometry (methods), Antioxidants (therapeutic use), Bone Demineralization, Pathologic (drug therapy), Bone Demineralization, Pathologic (etiology), Bone Demineralization, Pathologic (pathology), Bone Density (drug effects), Collagen Type I (metabolism), Female, Follow-Up Studies, Homocysteine (metabolism), Humans, Male, Middle Aged, Parkinson Disease (complications), Peptides (metabolism), Thioctic Acid (therapeutic use).
- MESH :
- chemical , metabolism : Collagen Type I, Homocysteine, Peptides.
- chemical , therapeutic use : Antioxidants, Thioctic Acid.
- complications : Parkinson Disease.
- drug effects : Bone Density.
- drug therapy : Bone Demineralization, Pathologic.
- etiology : Bone Demineralization, Pathologic.
- methods : Absorptiometry, Photon, Anthropometry.
- pathology : Bone Demineralization, Pathologic.
- Aged, Analysis of Variance, Female, Follow-Up Studies, Humans, Male, Middle Aged.
Abstract
We investigated whether homocysteine (Hcy)- lowering therapy or an antioxidant prevented bone loss in Parkinson's disease (PD) patients taking levodopa. Forty-two PD patients with low bone mineral density (BMD) taking levodopa were randomly assigned to Hcy-lowering therapy (5 mg folate and 1500 microg vitamin B(12) daily), alpha-lipoic acid (alpha-LA) therapy (1200 mg daily), or control groups. Primary outcomes were BMD changes from baseline to 12 months. Secondary outcomes were changes in Hcy level, and C-telopeptide (CTX) levels at 12 months. Forty-one patients completed the study. Hcy-lowering therapy resulted in significantly greater BMD changes at the lumbar spine (4.4%), total femur (2.8%), and femur shaft (2.8%) than control (P = 0.005-0.023). BMD changes in the alpha-LA therapy group were similar to those of the control group, but changes at the trochanter (4.6%) were significantly greater in the alpha-LA therapy group than in the control group after adjustment for body mass index changes. Hcy concentrations decreased to 35.2% +/- 13.4% in the Hcy-lowering therapy group, but increased in other groups. Serum CTX levels at 12 months tended to be lower in the Hcy-lowering group (0.442 +/- 0.024 ng/mL) than control group (0.628 +/- 0.039 ng/mL) (P = 0.159). This small trial suggests that Hcy-lowering therapy may prevent bone loss in PD patients taking levodopa.
DOI: 10.1002/mds.22866
PubMed: 19938151
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A79
Links to Exploration step
pubmed:19938151Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease.</title>
<author><name sortKey="Lee, Seung Hun" sort="Lee, Seung Hun" uniqKey="Lee S" first="Seung Hun" last="Lee">Seung Hun Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Mi Jung" sort="Kim, Mi Jung" uniqKey="Kim M" first="Mi Jung" last="Kim">Mi Jung Kim</name>
</author>
<author><name sortKey="Kim, Beom Jun" sort="Kim, Beom Jun" uniqKey="Kim B" first="Beom-Jun" last="Kim">Beom-Jun Kim</name>
</author>
<author><name sortKey="Kim, Sung Reul" sort="Kim, Sung Reul" uniqKey="Kim S" first="Sung Reul" last="Kim">Sung Reul Kim</name>
</author>
<author><name sortKey="Chun, Sail" sort="Chun, Sail" uniqKey="Chun S" first="Sail" last="Chun">Sail Chun</name>
</author>
<author><name sortKey="Ryu, Jin Sook" sort="Ryu, Jin Sook" uniqKey="Ryu J" first="Jin Sook" last="Ryu">Jin Sook Ryu</name>
</author>
<author><name sortKey="Kim, Ghi Su" sort="Kim, Ghi Su" uniqKey="Kim G" first="Ghi Su" last="Kim">Ghi Su Kim</name>
</author>
<author><name sortKey="Lee, Myoung Chong" sort="Lee, Myoung Chong" uniqKey="Lee M" first="Myoung Chong" last="Lee">Myoung Chong Lee</name>
</author>
<author><name sortKey="Koh, Jung Min" sort="Koh, Jung Min" uniqKey="Koh J" first="Jung-Min" last="Koh">Jung-Min Koh</name>
</author>
<author><name sortKey="Chung, Sun Ju" sort="Chung, Sun Ju" uniqKey="Chung S" first="Sun Ju" last="Chung">Sun Ju Chung</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="doi">10.1002/mds.22866</idno>
<idno type="RBID">pubmed:19938151</idno>
<idno type="pmid">19938151</idno>
<idno type="wicri:Area/PubMed/Corpus">001A79</idno>
<idno type="wicri:Area/PubMed/Curation">001A79</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease.</title>
<author><name sortKey="Lee, Seung Hun" sort="Lee, Seung Hun" uniqKey="Lee S" first="Seung Hun" last="Lee">Seung Hun Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Mi Jung" sort="Kim, Mi Jung" uniqKey="Kim M" first="Mi Jung" last="Kim">Mi Jung Kim</name>
</author>
<author><name sortKey="Kim, Beom Jun" sort="Kim, Beom Jun" uniqKey="Kim B" first="Beom-Jun" last="Kim">Beom-Jun Kim</name>
</author>
<author><name sortKey="Kim, Sung Reul" sort="Kim, Sung Reul" uniqKey="Kim S" first="Sung Reul" last="Kim">Sung Reul Kim</name>
</author>
<author><name sortKey="Chun, Sail" sort="Chun, Sail" uniqKey="Chun S" first="Sail" last="Chun">Sail Chun</name>
</author>
<author><name sortKey="Ryu, Jin Sook" sort="Ryu, Jin Sook" uniqKey="Ryu J" first="Jin Sook" last="Ryu">Jin Sook Ryu</name>
</author>
<author><name sortKey="Kim, Ghi Su" sort="Kim, Ghi Su" uniqKey="Kim G" first="Ghi Su" last="Kim">Ghi Su Kim</name>
</author>
<author><name sortKey="Lee, Myoung Chong" sort="Lee, Myoung Chong" uniqKey="Lee M" first="Myoung Chong" last="Lee">Myoung Chong Lee</name>
</author>
<author><name sortKey="Koh, Jung Min" sort="Koh, Jung Min" uniqKey="Koh J" first="Jung-Min" last="Koh">Jung-Min Koh</name>
</author>
<author><name sortKey="Chung, Sun Ju" sort="Chung, Sun Ju" uniqKey="Chung S" first="Sun Ju" last="Chung">Sun Ju Chung</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Absorptiometry, Photon (methods)</term>
<term>Aged</term>
<term>Analysis of Variance</term>
<term>Anthropometry (methods)</term>
<term>Antioxidants (therapeutic use)</term>
<term>Bone Demineralization, Pathologic (drug therapy)</term>
<term>Bone Demineralization, Pathologic (etiology)</term>
<term>Bone Demineralization, Pathologic (pathology)</term>
<term>Bone Density (drug effects)</term>
<term>Collagen Type I (metabolism)</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Homocysteine (metabolism)</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (complications)</term>
<term>Peptides (metabolism)</term>
<term>Thioctic Acid (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Collagen Type I</term>
<term>Homocysteine</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antioxidants</term>
<term>Thioctic Acid</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Bone Density</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bone Demineralization, Pathologic</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Bone Demineralization, Pathologic</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Absorptiometry, Photon</term>
<term>Anthropometry</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Bone Demineralization, Pathologic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Analysis of Variance</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We investigated whether homocysteine (Hcy)- lowering therapy or an antioxidant prevented bone loss in Parkinson's disease (PD) patients taking levodopa. Forty-two PD patients with low bone mineral density (BMD) taking levodopa were randomly assigned to Hcy-lowering therapy (5 mg folate and 1500 microg vitamin B(12) daily), alpha-lipoic acid (alpha-LA) therapy (1200 mg daily), or control groups. Primary outcomes were BMD changes from baseline to 12 months. Secondary outcomes were changes in Hcy level, and C-telopeptide (CTX) levels at 12 months. Forty-one patients completed the study. Hcy-lowering therapy resulted in significantly greater BMD changes at the lumbar spine (4.4%), total femur (2.8%), and femur shaft (2.8%) than control (P = 0.005-0.023). BMD changes in the alpha-LA therapy group were similar to those of the control group, but changes at the trochanter (4.6%) were significantly greater in the alpha-LA therapy group than in the control group after adjustment for body mass index changes. Hcy concentrations decreased to 35.2% +/- 13.4% in the Hcy-lowering therapy group, but increased in other groups. Serum CTX levels at 12 months tended to be lower in the Hcy-lowering group (0.442 +/- 0.024 ng/mL) than control group (0.628 +/- 0.039 ng/mL) (P = 0.159). This small trial suggests that Hcy-lowering therapy may prevent bone loss in PD patients taking levodopa.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19938151</PMID>
<DateCreated><Year>2010</Year>
<Month>03</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted><Year>2010</Year>
<Month>06</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>25</Volume>
<Issue>3</Issue>
<PubDate><Year>2010</Year>
<Month>Feb</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>332-40</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22866</ELocationID>
<Abstract><AbstractText>We investigated whether homocysteine (Hcy)- lowering therapy or an antioxidant prevented bone loss in Parkinson's disease (PD) patients taking levodopa. Forty-two PD patients with low bone mineral density (BMD) taking levodopa were randomly assigned to Hcy-lowering therapy (5 mg folate and 1500 microg vitamin B(12) daily), alpha-lipoic acid (alpha-LA) therapy (1200 mg daily), or control groups. Primary outcomes were BMD changes from baseline to 12 months. Secondary outcomes were changes in Hcy level, and C-telopeptide (CTX) levels at 12 months. Forty-one patients completed the study. Hcy-lowering therapy resulted in significantly greater BMD changes at the lumbar spine (4.4%), total femur (2.8%), and femur shaft (2.8%) than control (P = 0.005-0.023). BMD changes in the alpha-LA therapy group were similar to those of the control group, but changes at the trochanter (4.6%) were significantly greater in the alpha-LA therapy group than in the control group after adjustment for body mass index changes. Hcy concentrations decreased to 35.2% +/- 13.4% in the Hcy-lowering therapy group, but increased in other groups. Serum CTX levels at 12 months tended to be lower in the Hcy-lowering group (0.442 +/- 0.024 ng/mL) than control group (0.628 +/- 0.039 ng/mL) (P = 0.159). This small trial suggests that Hcy-lowering therapy may prevent bone loss in PD patients taking levodopa.</AbstractText>
<CopyrightInformation>(c) 2009 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Seung Hun</ForeName>
<Initials>SH</Initials>
<AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Mi Jung</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Beom-Jun</ForeName>
<Initials>BJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Sung Reul</ForeName>
<Initials>SR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chun</LastName>
<ForeName>Sail</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ryu</LastName>
<ForeName>Jin Sook</ForeName>
<Initials>JS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Ghi Su</ForeName>
<Initials>GS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Myoung Chong</ForeName>
<Initials>MC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Koh</LastName>
<ForeName>Jung-Min</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chung</LastName>
<ForeName>Sun Ju</ForeName>
<Initials>SJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D024042">Collagen Type I</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C052929">collagen type I trimeric cross-linked peptide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0LVT1QZ0BA</RegistryNumber>
<NameOfSubstance UI="D006710">Homocysteine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>73Y7P0K73Y</RegistryNumber>
<NameOfSubstance UI="D008063">Thioctic Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015502">Absorptiometry, Photon</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000704">Analysis of Variance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000886">Anthropometry</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000975">Antioxidants</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018488">Bone Demineralization, Pathologic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D015519">Bone Density</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D024042">Collagen Type I</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006710">Homocysteine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010455">Peptides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008063">Thioctic Acid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>11</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>11</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>6</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.22866</ArticleId>
<ArticleId IdType="pubmed">19938151</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A79 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001A79 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:19938151 |texte= Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:19938151" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |